Dermatology

Stay updated with the latest healthcare breakthroughs, including FDA regulatory decisions, phase 3 data, and new clinical guidelines.

New findings point to remaining gaps in AI diagnostic success for skin lesions compared with experienced clinicians in dermatology.

Vleugels discusses Part B findings on investigational IL-13 inhibitor zumilokibart (APG777) in adult patients with moderate-to-severe atopic dermatitis.

Krakowski and Torres-Zegarra discuss how to initiate the conversation about systemic therapy with families and review the guideline's drug hierarchy.

The experts review the guideline's approach to topicals for active atopic dermatitis, covering the appropriate use of topical corticosteroids and more.

This segment examines how the guideline navigates the tension between GRADE-based evidence thresholds and long-established clinical practices.

This discussion highlights disease prevention and the foundational role of moisturization, with the experts examining emollient use.

Pediatric dermatologists introduce the first pediatric-specific evidence-based guidelines for atopic dermatitis and discuss.

This Q&A interview highlights findings on the lifelong impacts on education and career faced by some patients with childhood diagnoses of atopic dermatitis.

This installment of our Month in Review series highlights top news headlines and podcast updates in dermatology from May 2026.

The Genital Psoriasis Wellness Consortium reached consensus on age-specific recommendations on screening, care, and special populations.

Delphine Kerob, MD, in this segment of her interview, expanded on the clinical implications of new data on atopic dermatitis and lifelong impacts.

A study revealed adults with childhood onset atopic dermatitis may see greater limitations in career and educational options.

Jonathan Bernstein, MD, discusses remibrutinib, c-kit inhibitors, and the current limits of biomarker-guided decision-making in chronic spontaneous urticaria.

The latest ABCs of Dermatology explored the future potential of amlitelimab in atopic dermatitis and the potential of OX40 ligand-targeted therapy.

This interview highlights key facts regarding HS in honor of Hidradenitis Suppurativa (HS) Awareness Week, featuring Kiera Booth, MD.

This segment of the Skin of Color Savvy podcast highlights how dermatologists can improve sunscreen adherence among individuals with skin of color.

Bernstein discussed the evolving role of biomarkers in chronic spontaneous urticaria at EAC 2026.

This interview highlights topline findings from Part B of the phase 2 APEX trial highlight the efficacy of zumilokibart (APG777) in adults with atopic dermatitis.

This segment of the May episode of The Medical Sisterhood highlights the importance of addressing patients' and parents' fears in dermatology.

Amlitelimab was discussed in the ABCs in Dermatology podcast, with the hosts highlighting atopic dermatitis patient demographics and high disease burden.

In a recent episode of The Medical Sisterhood podcast, Lisa Swanson, MD, spoke about the importance of female mentorship in medicine.

This segment of the latest Skin of Color Savvy podcast highlighted persistent disparities in skin cancer prevention, awareness, and diagnosis.

Explore OX40/OX40L inhibition in atopic dermatitis: phase 3 amlitelimab efficacy, safety signals, and what upstream immune control could mean.

These topline findings from Part B of the phase 2 APEX trial highlight the efficacy of zumilokibart (APG777) in adults with moderate-to-severe atopic dermatitis.